Clinical Trial: A Study to Assess the Effect of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Chronic Angle-closure Glaucoma
Study Status: Completed
Recruit Status: Unknown status
Study Type: Interventional
Official Title: A Prospective Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Chronic Angle-closure Glaucoma
Brief Summary:
To evaluate the ocular hypotensive efficacy of Rho kinase Inhibitor (AR-12286 0.5% and 0.7%) ophthalmic solutions in patients diagnosed with chronic angle-closure glaucoma treated for 6 months.
Secondary Outcome
Secondary objectives are:
- To evaluate the early effect of Rho kinase Inhibitor (AR-12286) in reducing intraocular pressure (IOP).
- To evaluate the long term effect of the drug on IOP.
- To determine if AR-12286 can be used as directed therapy for CACG, reducing or eliminating the structural blockage of the trabecular meshwork that leads to development of elevated IOP.
Detailed Summary:
Sponsor: New York Glaucoma Research Institute
Current Primary Outcome: Long Lasting effect of study drug to reduce IOP [ Time Frame: 6 Months ]
Original Primary Outcome: Same as current
Current Secondary Outcome: Secondary Outcome [ Time Frame: 6 Months ]
Original Secondary Outcome: Same as current
Information By: New York Glaucoma Research Institute
Dates:
Date Received: May 23, 2014
Date Started: May 2014
Date Completion:
Last Updated: April 23, 2015
Last Verified: April 2015